Back to top
more

Anika Therapeutics (ANIK)

(Real Time Quote from BATS)

$8.51 USD

8.51
57,201

-0.13 (-1.51%)

Updated Aug 4, 2025 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of 0.00% and +4.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Company News for May 12, 2025

by Zacks Equity Research

Companies in The News Are: ENB,PAA,ANIK,GOGO

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -166.67% and 8.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vericel (VCEL) delivered earnings and revenue surprises of -155.56% and 2.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in Anika Therapeutics Stock?

by Zacks Equity Research

Investors need to pay close attention to ANIK stock based on the movements in the options market lately.

Zacks Equity Research

Are Options Traders Betting on a Big Move in Anika Therapeutics (ANIK) Stock?

by Zacks Equity Research

Investors need to pay close attention to Anika Therapeutics (ANIK) stock based on the movements in the options market lately.

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -133.33% and 2.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences (RNA) delivered earnings and revenue surprises of 4.76% and 29.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?

by Zacks Equity Research

Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

New Strong Sell Stocks for November 11th

by Zacks Equity Research

AMRK, ANIK and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 11, 2024.

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -183.33% and 8.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -26.09% and 5.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Philips' (PHG) first-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.

Zacks Equity Research

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Zacks Equity Research

Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.

Zacks Equity Research

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -69.89% and 2.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

New Strong Buy Stocks for December 14th

by Zacks Equity Research

MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.

Zacks Equity Research

Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion

by Zacks Equity Research

Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.

Zacks Equity Research

Apellis (APLS) Provides Syfovre Q3 Preliminary Revenues Guidance

by Zacks Equity Research

Apellis' (APLS) shares rise as it provides third-quarter 2023 preliminary revenues guidance for Syfovre, approved for the treatment of geographic atrophy.